CULLINAN THERAPEUTICS INC (CGEM) Stock Analyst Earnings Estimates
NASDAQ:CGEM - Nasdaq - US2300311063 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 18.94M | 141.16M -100.00% | 29.012M | 44.513M 53.43% | 22.804M -48.77% | 138.52M 507.44% | 331.32M 139.19% | 1.339B 304.14% | ||||||
| EBITDA YoY % growth | -22.2M -52.58% | -60.28M -171.53% | -67.9M -12.64% | 147.98M -91.53% | -195.671M -46.36% | -198.123M -3.30% | -229.465M -16.71% | -202.238M 11.87% | -172.721M 14.60% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -22.27M -52.64% | -60.34M -170.95% | -67.95M -12.61% | 148.39M -91.52% | -196.334M -46.50% | -197.881M -3.29% | -233.365M -18.51% | -220.72M 5.42% | -235.582M -6.73% | -290.446M -23.29% | -273.575M 5.81% | -148.121M 45.86% | 1.297B 975.63% | |
| Operating Margin | N/A | N/A | -358.76% | 105.12% | N/A | N/A | N/A | -760.79% | -529.24% | -1,273.66% | -197.50% | -44.71% | 96.86% | |
| EPS YoY % growth | N/A | N/A | -1.50 9.41% | 2.38 258.00% | -4.17 -255.70% | -3.12 17.89% | -3.32 -9.46% | -3.07 7.43% | -2.89 5.84% | -3.36 -16.08% | -3.52 -4.86% | -0.14 95.94% | 15.96 11,278.57% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.85 -13.29% | -0.84 -22.42% | -0.83 -13.55% | -0.91 -23.18% | -0.64 24.37% | -0.69 17.89% | -0.74 10.17% |
| Revenue Q2Q % growth | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | -57.191M -14.67% | -58.334M -19.96% | -59.497M -8.69% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -59.75M -19.44% | -58.86M -20.48% | -60.607M -10.10% | -60.69M -10.35% | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.74 13.95% | -0.82 | 0.08 | 9.46% |
| Q4 2024 Q2Q % growth | -0.73 -35.19% | -0.77 | 0.04 | 5.54% |
| Q3 2024 Q2Q % growth | -0.69 24.18% | -0.82 | 0.13 | 16.07% |
| Q2 2024 Q2Q % growth | -0.75 8.54% | -0.74 | -0.01 | -1.34% |
| Q1 2024 Q2Q % growth | -0.86 39.44% | -1.01 | 0.15 | 14.81% |
| Q4 2023 Q2Q % growth | -0.54 8.47% | -0.98 | 0.44 | 44.93% |
| Q3 2023 Q2Q % growth | -0.91 -68.52% | -0.94 | 0.03 | 3.20% |
| Q2 2023 Q2Q % growth | -0.82 -121.75% | -0.99 | 0.17 | 17.12% |
| Q1 2023 Q2Q % growth | -1.42 -425.93% | -1.00 | -0.42 | -42.06% |
| Q4 2022 Q2Q % growth | -0.59 20.27% | -0.68 | 0.09 | 13.02% |
| Q3 2022 Q2Q % growth | -0.54 -35.00% | -0.99 | 0.45 | 45.23% |
| Q2 2022 Q2Q % growth | 3.77 1,147.22% | 5.53 | -1.76 | -31.76% |
| Q1 2022 Q2Q % growth | -0.27 | -0.62 | 0.35 | 56.61% |
| Q4 2021 Q2Q % growth | -0.74 74.13% | -0.48 | -0.26 | -53.27% |
| Q3 2021 Q2Q % growth | -0.40 | -0.43 | 0.03 | 7.36% |
| Q2 2021 Q2Q % growth | -0.36 | -0.42 | 0.06 | 14.95% |
| Q1 2021 Q2Q % growth | 0.00 | 0.07 | -0.07 | -100.00% |
| Q4 2020 Q2Q % growth | -2.86 | -0.39 | -2.47 | -628.29% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | 280.5M | -280.5M | -100.00% | |
| Q1 2022 Q2Q % growth | -100.00% | % | ||
| Q1 2021 Q2Q % growth | 18.94M | 19.38M | -440K | -2.27% |
| Q4 2020 Q2Q % growth | 9.18M | -9.18M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -4.83% | -0.63% | 0% | 1.17% |
| Revenue | N/A | N/A | N/A | N/A |